Previous studies have found that ABCB6 (34), CDKN2A (35), CDKN3 (36), and TPI1 (37) (catalyzing the conversion of dihydroxyacetone phosphate (DHAP) and D-type glyceraldehyde 3-phosphate (G3P)), as well as HSPA8 (38), were potential targets for the treatment of liver cancer, which is consistent with our analysis results. This evidence concerns the gene ABCB6 and liver cancer.